Small Molecule Drugs

Small Molecule Drugs includes companies developing orally available or otherwise chemically synthesized medicines built from relatively low-molecular-weight compounds. This remains one of the broadest and most commercially important categories in biotech and pharma.

Why watch Small Molecule Drugs

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Small Molecule Drugs news

The latest feed items from companies currently grouped under Small Molecule Drugs.

1. 01
   2026-10-06 14:00 EST

   GSKViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia

   Source: GSK plc

2. 02
   2026-10-05 12:00 EST

   PMVPPMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

   Source: PMV Pharmaceuticals

3. 03
   2026-10-05 11:00 EST

   BCRXBioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

   Source: BioCryst Pharmaceuticals

4. 04
   2026-10-01 21:10 EST

   ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   Source: Zentalis

5. 05
   2026-10-01 06:00 EST

   RHHBYRoche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

   Source: Roche Holdings AG

6. 06
   2026-10-01 05:00 EST

   RHHBYRoche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine

   Source: Roche Holdings AG

7. 07
   2026-09-30 05:00 EST

   RHHBYRoche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

   Source: Roche Holdings AG

8. 08
   2026-09-29 05:00 EST

   PHARPharming announces CEO transition

   Source: Pharming Group

9. 09
   2026-09-28 17:58 EST

   JNJUna nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima linea

   Source: Johnson & Johnson

10. 10
    2026-09-28 17:48 EST

    JNJEine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definieren

    Source: Johnson & Johnson

11. 11
    2026-09-28 17:44 EST

    JNJUne nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement

    Source: Johnson & Johnson

12. 12
    2026-09-28 12:19 EST

    JNJL’administration d’une seule perfusion de CARVYKTI®▼ (ciltacabtagène autoleucel) a permis d’obtenir une rémission sans traitement pendant cinq ans chez 50 pour cent des patients atteints d’un myélome multiple en rechute/réfractaire traité à un stade précoce du parcours thérapeutique

    Source: Johnson & Johnson

13. 13
    2026-09-25 14:30 EST

    PHARPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

    Source: Pharming Group

14. 14
    2026-09-25 11:16 EST

    JNJSingle infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

    Source: Johnson & Johnson

15. 15
    2026-09-23 14:07 EST

    JNJNew model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

    Source: Johnson & Johnson

16. 16
    2026-09-23 05:15 EST

    RHHBYPositive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

    Source: Roche Holdings AG

17. 17
    2026-09-23 05:00 EST

    RHHBYÄnderung im Verwaltungsrat von Roche

    Source: Roche Holdings AG

18. 18
    2026-09-23 05:00 EST

    RHHBYChange in Roche’s Board of Directors

    Source: Roche Holdings AG

19. 19
    2026-09-22 11:01 EST

    JNJLe CHMP recommande l’approbation de TECVAYLI®▼ (teclistamab) de Johnson & Johnson pour le traitement du myélome multiple en rechute/réfractaire après au moins un traitement antérieur

    Source: Johnson & Johnson

20. 20
    2026-09-22 11:01 EST

    JNJDer CHMP empfiehlt die Zulassung von TECVAYLI®▼ (teclistamab) von Johnson & Johnson zur Behandlung des rezidivierten bzw. refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie

    Source: Johnson & Johnson

Companies in Small Molecule Drugs

21 companies tagged with Small Molecule Drugs.

Frequently Asked Questions